Myocardial protection during elective coronary artery bypasses grafting by pretreatment with omega-3 polyunsaturated

Milić Veljović1, Ana Popadić, Zoran Vukić

  • 1Clinic of Anesthesiology and Intensive Care, Clinic of Cardiac Surgery, Military Medical Academy, Belgrade, Serbia. milic1210@yahoo.com

Insights

Preoperative omega-3 polyunsaturated fatty acids (PUFAs) infusion improved early metabolic recovery and myocardial protection in patients undergoing coronary artery bypass grafting (CABG) with cardiopulmonary bypass (CPB). This suggests omega-3 PUFAs are a safe and effective cardioprotective adjunct during CPB.

Area of Science:

  • Cardiology
  • Cardiovascular Surgery
  • Biochemistry

Background:

  • Coronary artery bypass grafting (CABG) with cardiopulmonary bypass (CPB) can cause myocardial injury.
  • Previous attempts to mitigate CPB-induced injury with various agents yielded inconsistent results.
  • Omega-3 polyunsaturated fatty acids (PUFAs) have demonstrated cardioprotective effects in preclinical studies.

Purpose of the Study:

  • To evaluate the efficacy of preoperative intravenous omega-3 PUFAs in preventing ischemia-reperfusion injury during CPB in CABG patients.
  • To assess the impact of omega-3 PUFAs on myocardial metabolic recovery and injury markers.

Main Methods:

  • Prospective, randomized, placebo-controlled study with parallel groups.
  • 20 patients received preoperative intravenous omega-3 PUFAs infusion; 20 received saline placebo.
  • Blood samples analyzed for lactate extraction, oxygen extraction, troponin I (TnT), and creatine kinase-myocardial band (CK-MB) levels at various time points.

Main Results:

  • Omega-3 PUFAs group showed significantly improved lactate extraction and higher myocardial oxygen extraction post-reperfusion compared to placebo.
  • Significantly lower levels of TnT and CK-MB (at 4 hours) were observed in the omega-3 PUFAs group.
  • No significant differences in lactate extraction at 30 minutes post-reperfusion or CK-MB at 24 hours were noted between groups.

Conclusions:

  • Preoperative omega-3 PUFAs administration promotes early cardiac metabolic recovery and enhances myocardial protection following CABG with CPB.
  • Omega-3 PUFAs emulsion can be considered a safe and effective cardioprotective agent, beyond its nutritional role, during CPB.
  • Further research may explore optimal dosing and long-term outcomes.
Abstract

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...